MiniMed Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MMEDV research report →
Price Chart
About the company
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories.
- CEO
- Que Thanh Dallara
- IPO
- 2026
- Employees
- 8,000
- HQ
- Northridge, CA, US
Get TickerSpark's AI analysis on MMEDV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $495.60M
- P/E
- -13.39
- PEG
- 0.13
- P/S
- 1.40
- P/B
- 1.24
- EV/EBITDA
- 25.78
- Div Yield
- 0.00%
- Gross Margin
- 53.85%
- Op Margin
- 0.53%
- Net Margin
- -10.21%
- ROE
- -9.11%
- ROIC
- 0.43%
- 52W High
- $21.50
- 52W Low
- $15.50
- 50D MA
- $18.72
- 200D MA
- $18.72
- Beta
- -2.86
- Avg Volume
- 43.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MiniMed delivered a strong Q1 with 15.8% organic revenue growth, raised full-year revenue guidance, and advanced multiple launches and pipeline milestones ahead of schedule.· September 1, 2026
- Q1 revenue was $843 million, with 15.8% organic growth; U.S. grew 13.1% and international grew 16.9%.
- Adjusted EBITDA margin was 9.9%, but would have been 12.2% excluding an $8 million investment pull-forward and a $12 million FX remeasurement charge.
- Management raised fiscal 2027 organic revenue growth guidance to approximately 10.5% from about 10% and reaffirmed adjusted EBITDA margin guidance of approximately 16%.
- Flex, launched late in Q1, drove U.S. momentum; new U.S. pumps sold were up over 20%, and new MiniMed prescribers were up 24%.
- Pipeline progress came early: Flex got CE Mark, Fit filing was completed ahead of plan, Vivera enrollment finished ahead of schedule, and a next-gen extended wear sensor got FDA IDE approval.
Q1 revenue was $843 million, up 15.8% organically. U.S. revenue grew 13.1% and international revenue grew 16.9%, with the extra week contributing approximately 4 to 6 points of Q1 growth; excluding that week, organic growth was in the low double digits versus 8.7% in Q4. Adjusted gross margin was 55.9%, adjusted EBITDA was $83 million, and adjusted EBITDA margin was 9.9%; excluding the $8 million investment pull-forward and the $12 million FX remeasurement charge, adjusted EBITDA margin would have been 12.2%. New pumps sold were 34,000, up 7.7% year over year, and CGM attachment rate was 69%, up 500 basis points year over year. For fiscal 2027, management raised organic revenue growth guidance to approximately 10.5% from approximately 10% and reaffirmed adjusted EBITDA margin guidance of approximately 16%.
Que Dallara framed the quarter as evidence that MiniMed’s commercial strategy and product pipeline are working together, saying the company had an “excellent start” as a stand-alone public company. She highlighted Flex, Go, Fit, Vivera, and the next-gen sensor as part of a single ecosystem strategy rather than isolated launches. Her tone was confident and upbeat, emphasizing that the company is moving its timelines left and building a broader platform for insulin-taking patients across pump, patch pump, and smart pen options.
Chad Spooner focused on the financial acceleration and margin profile. He cited Q1 revenue of $843 million, adjusted EBITDA of $83 million, adjusted EBITDA margin of 9.9%, and adjusted gross margin of 55.9%. He said the $8 million in pulled-forward investment and the $12 million FX remeasurement charge were timing-related or nonoperational, and that underlying EBITDA margin would have been 12.2% absent those items. He also noted approximately $207 million of cash, no debt, an undrawn $500 million revolver, and negative free cash flow of $90 million in Q1, which included $111 million of separation and stand-up activity; excluding those items, free cash flow would have been positive $21 million.
Analysts focused on Fit launch capacity, Vivera’s remaining approval steps, patient deferrals ahead of new launches, Type 2 retention, and competitive pressure internationally. Management said it is planning for multiple scenarios on Fit, is already working beyond the 20,000-patient launch capacity, and expects to be ready for commercialization regardless of timing. On Vivera, management said the trial is complete and the next steps are database lock, analytics, and submission. On deferrals and retention, management said it has incorporated waiting-mode assumptions into the forecast, does not see alarming Type 2 attrition, and believes improved onboarding and retention programs help support long-term persistence.
The bull case from this call is that MiniMed is seeing broad-based demand acceleration while multiple new products are landing earlier than planned. Flex appears to be expanding the installed base, with new pumps sold up over 20%, new prescribers up 24%, and strong patient and physician response; international momentum also looks solid, with double-digit growth and early gains from new sensors and launches. Management is also signaling a stronger product and margin setup ahead, with better-than-expected Simplera yields, a pipeline that could deepen the ecosystem, and raised revenue guidance.
The bear case is that near-term margin and cash generation still reflect launch spending, FX volatility, and stand-up costs, with Q1 free cash flow negative $90 million and separation-related uses consuming most of that. The company also acknowledged that some Q1 growth was helped by an extra week, so reported growth will normalize in coming quarters. In addition, management still faces execution risk on multiple launches, FDA timing uncertainty for Fit and Vivera, and competitive pressure in contested international markets, even if management is currently encouraged by the data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- —
- Shares Outstanding
- 28.00M
- Float Shares
- 27.17M
Our MMEDV coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MMEDV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
